Gilead Sciences (NASDAQ:GILD)‘s stock had its “hold” rating reaffirmed by Robert W. Baird in a research note issued on Monday, TipRanks reports. They currently have a $76.00 price objective on the biopharmaceutical company’s stock. Robert W. Baird’s target price would suggest a potential downside of 1.22% from the stock’s previous close.
Several other equities analysts have also weighed in on GILD. SVB Leerink upgraded shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and upped their price objective for the company from $85.00 to $94.00 in a report on Wednesday, June 3rd. Mizuho reiterated a “buy” rating and set a $81.00 price objective on shares of Gilead Sciences in a report on Wednesday, May 13th. Royal Bank of Canada reiterated a “buy” rating and set a $88.00 price objective on shares of Gilead Sciences in a report on Wednesday, June 3rd. Cfra upped their target price on shares of Gilead Sciences from $71.00 to $74.00 and gave the stock a “sell” rating in a report on Wednesday, April 29th. Finally, BMO Capital Markets lowered shares of Gilead Sciences from an “outperform” rating to a “market perform” rating and set a $79.00 target price on the stock. in a report on Monday, April 20th. Five investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and ten have given a buy rating to the company. Gilead Sciences presently has a consensus rating of “Hold” and a consensus price target of $79.65.
GILD stock opened at $76.94 on Monday. The firm has a market cap of $96.51 billion, a price-to-earnings ratio of 19.78, a PEG ratio of 3.37 and a beta of 0.68. The company has a quick ratio of 2.92, a current ratio of 3.04 and a debt-to-equity ratio of 1.00. Gilead Sciences has a 12-month low of $60.89 and a 12-month high of $85.97. The company’s fifty day simple moving average is $75.41 and its 200 day simple moving average is $72.02.
Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 30th. The biopharmaceutical company reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.57 by $0.11. Gilead Sciences had a net margin of 21.84% and a return on equity of 35.44%. The firm had revenue of $5.55 billion for the quarter, compared to analyst estimates of $5.44 billion. During the same quarter in the prior year, the business earned $1.67 earnings per share. The business’s quarterly revenue was up 5.1% compared to the same quarter last year. Research analysts expect that Gilead Sciences will post 6.4 earnings per share for the current year.
In other news, Director John Francis Cogan sold 2,413 shares of the stock in a transaction that occurred on Monday, April 20th. The shares were sold at an average price of $83.00, for a total transaction of $200,279.00. Following the completion of the transaction, the director now directly owns 57,273 shares of the company’s stock, valued at approximately $4,753,659. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Brett A. Pletcher sold 13,210 shares of the stock in a transaction that occurred on Tuesday, May 5th. The shares were sold at an average price of $79.23, for a total transaction of $1,046,628.30. Following the transaction, the executive vice president now directly owns 27,204 shares of the company’s stock, valued at $2,155,372.92. The disclosure for this sale can be found here. Insiders have sold a total of 37,731 shares of company stock valued at $3,008,736 over the last three months. Insiders own 0.13% of the company’s stock.
Institutional investors have recently added to or reduced their stakes in the company. Mid Atlantic Financial Management Inc. ADV lifted its stake in shares of Gilead Sciences by 13.0% during the 4th quarter. Mid Atlantic Financial Management Inc. ADV now owns 15,764 shares of the biopharmaceutical company’s stock valued at $1,024,000 after buying an additional 1,813 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS lifted its stake in shares of Gilead Sciences by 0.4% during the 4th quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 81,471 shares of the biopharmaceutical company’s stock valued at $5,294,000 after buying an additional 317 shares in the last quarter. Key Financial Inc purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at approximately $262,000. Capital One National Association purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at approximately $543,000. Finally, Wellington Shields & Co. LLC purchased a new stake in shares of Gilead Sciences during the 4th quarter valued at approximately $809,000. 80.15% of the stock is owned by hedge funds and other institutional investors.
Gilead Sciences Company Profile
Gilead Sciences, Inc, a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, and Truvada for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, and Viread products for treating liver diseases.
Featured Article: Understanding Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.